Business
Faridoxorubicin Phase 1b SGC data
Avacta Group PLC announced compelling preliminary Phase 1b data for faridoxorubicin (AVA6000) in salivary gland cancer patients, demonstrating clinically meaningful tumor shrinkage and a combined disease control rate of 90% across Phase 1a and 1b cohorts, with two confirmed partial responses and seven minor responses observed. These results are consistent with Phase 1a data, showing robust anti-tumor activity and a favorable safety profile, leading to continued enrollment in the Phase 1b cohort with further data updates expected in the first half of 2026. Disclaimer*
About this update from Avacta Group Plc
[{"type":"text","content":"\n\n \nFaridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers\n \nPreliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in September 2025\n \nCombined disease control rate of 90% across both Phase 1a and Phase 1b patients with confirmed partial and minor responses observed\n \nLONDON and PHILADELPHIA - December 17, 2025 - Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced compelling new data in patients with salivary gland cancer (SGC) enrolled in the ongoing Phase 1b trial of faridoxorubicin (AVA6000). The data show confirmed partial and minor responses, consistent with data previously reported from the Phase 1a part of the study.\n \nFaridoxorubicin is the first peptide drug conjugate (PDC) in Avacta's pipeline. It consists of doxorubicin conjugated with Avacta's proprietary pre|CISION® peptide and is specifically cleaved (released) by fibroblast activation protein-alpha (FAP), which is over-expressed in the tumor microenvironment, enabling targeted release of the doxorubicin payload.\n \nSGC accounts for 6-8% of head and neck cancers, with approximately 2,500 cases diagnosed in the U.S. each year.1 SGC is a disease that does not respond to chemotherapy, has no standard therapy defined in the metastatic setting and a five-year survival rate of approximately 42%2 in advanced stage disease. \n \nAvacta's recent data demonstrate continued robust and meaningful tumor shrinkage in patients with SGCs and a combined disease control rate of 90% across Phase 1a and Phase 1b patients. \n \nBased on the preliminary favorable efficacy and safety data observed in the Phase 1b cohort in this part of the trial, enrollment will continue in this cohort with further data updates across the Phase 1a and Phase 1b cohorts expected in 1H 2026.\n \nChristina Coughlin MD, PhD, CEO of Avacta, commented:\n \n\"These data continue to reinforce our belief in the transformative potential of our pre|CISION® peptide drug conjugates to expand the therapeutic index and increase the efficacy of highly potent therapeutics and further strengthens our confide...